Prosecution Insights
Prosecution Insights
9 pending office actions • 9 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (22%) |
| §103 only | 4 (44%) |
| §112 only | 1 (11%) |
| Multi-statute (no §101) | 2 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIAMS, EMMALEE RAE | 1 | 0.0% | +0.0% |
| SHIAO, REI TSANG | 1 | 79.8% | -33.7% |
| NGUYEN, NAM P | 1 | 54.7% | +47.4% |
| LEE, SIN J | 1 | 68.9% | +25.5% |
| WANG, RUIXUE | 1 | 57.4% | +22.1% |
| MARCSISIN, ELLEN JEAN | 1 | 34.0% | +50.2% |
| MAHLUM, JONATHAN DAVIS | 1 | 51.5% | +20.8% |
| WU, JULIE ZHEN QIN | 1 | 61.6% | +52.1% |
| TRAN, CHRISTINA L | 1 | 48.2% | +45.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17698617 | METHODS OF SUPPRESSING MICROGLIAL ACTIVATION | WU, JULIE ZHEN QIN | 22d |
| 18477970 | LONG-TERM STABILIZATION, FORMULATION AND TABLETING OF LIVE MICROBIAL CELLS | WILLIAMS, EMMALEE RAE | — |
| 18268034 | BLOOD-BASED PROTEIN BIOMARKER PANEL FOR EARLY AND ACCURATE DETECTION OF CANCER | NGUYEN, NAM P | — |
| 18038392 | LONG-ACTING AND LONG-CIRCULATING DELIVERY VEHICLES | LEE, SIN J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17284919 | The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy | TRAN, CHRISTINA L | 37d overdue |
| 18014947 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Peptide Epitopes | WANG, RUIXUE | 19d overdue |
| 18012111 | Single Molecule Assays for Ultrasensitive Detection of Biomolecules | MARCSISIN, ELLEN JEAN | 8d overdue |
| 17698617 | METHODS OF SUPPRESSING MICROGLIAL ACTIVATION | WU, JULIE ZHEN QIN | 22d |
| 18268034 | BLOOD-BASED PROTEIN BIOMARKER PANEL FOR EARLY AND ACCURATE DETECTION OF CANCER | NGUYEN, NAM P | — |
| 18038392 | LONG-ACTING AND LONG-CIRCULATING DELIVERY VEHICLES | LEE, SIN J | — |
| 17766945 | Activators of Heme Regulated Inhibitor Kinase (HRI) | MAHLUM, JONATHAN DAVIS | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1691 | 1 |
| 1678 | 1 |
| 1613 | 1 |
| 1672 | 1 |
| 1677 | 1 |
| 1625 | 1 |
| 1644 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18477970 | LONG-TERM STABILIZATION, FORMULATION AND TABLETING OF LIVE MICROBIAL CELLS | WILLIAMS, EMMALEE RAE | 1653 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18278078 | INHIBITORS OF EPHB3 SIGNALING | SHIAO, REI TSANG | 1691 | §103 | Final Rejection | 70d | Pending | Aug 21, 2023 |
| 18268034 | BLOOD-BASED PROTEIN BIOMARKER PANEL FOR EARLY AND ACCURATE DETECTION OF CANCER | NGUYEN, NAM P | 1678 | §101§102§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18038392 | LONG-ACTING AND LONG-CIRCULATING DELIVERY VEHICLES | LEE, SIN J | 1613 | §102§112 | Non-Final OA | — | Pending | May 23, 2023 |
| 18014947 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Peptide Epitopes | WANG, RUIXUE | 1672 | §103 | Non-Final OA | 19d overdue | Pending | Jan 06, 2023 |
| 18012111 | Single Molecule Assays for Ultrasensitive Detection of Biomolecules | MARCSISIN, ELLEN JEAN | 1677 | §103Other | Final Rejection | 8d overdue | Pending | Dec 21, 2022 |
| 17766945 | Activators of Heme Regulated Inhibitor Kinase (HRI) | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | — | Pending | Apr 06, 2022 |
| 17698617 | METHODS OF SUPPRESSING MICROGLIAL ACTIVATION | WU, JULIE ZHEN QIN | 1644 | §103§112 | Non-Final OA | 22d | Pending | Mar 18, 2022 |
| 17284919 | The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy | TRAN, CHRISTINA L | 1637 | §112 | Final Rejection | 37d overdue | Pending | Apr 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial